Keywords: sutent, recommended, uk, 1st-line, mrcc, drug, global
Sutent recommended as UK 1st-line mRCC drug
Article | 18 May 2009
Global drug leviathan Pfizer's Sutent (sunitinib) has received a recommendation as a first-line treatment-of-choice for metastatic renal cell carcinoma in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
